Colo-rectal Cancer Clinical Trial
Official title:
Diagnostic Usefulness of Different Types of Gastrointestinal Endoscopic Investigations.
The number of endoscopies performed varies greatly between different countries and does not
reflect variations in disease incidents. The costs of unnecessary endoscopies are significant
and with a better selection of which patients need to be examined with endoscopy, resources
could be saved in healthcare, and a better triage would mean that malignancies and other more
serious conditions do not have to wait. An example of unnecessary endoscopy is a colonoscopy
in patients with irritable bowel syndrome or gastroscopy in patients with functional
dyspepsia.
The purpose of the project is, among other things:
- What diagnostic benefit have gastroscopy, colonoscopy, capsule endoscopy and double
balloon enteroscopy for different indications in different age groups?
- What are the risks of this type of examination?
- Can patients be better selected based on symptoms, psychometric data or laboratory
findings to reduce the number of unnecessary examinations and prioritize those that
should be scooped up first?
- Can changed calling methods reduce the number of late cancellations and rebookings and
missed patients?
1: Identification of colorectal cancer in Örebro Region - Effectiveness of Standardised
Course of Care.
Introduction: To shorten time to diagnosis of suspected colorectal cancer (CRC) in Sweden,
CRC was included in the "standardised course of care" (SCC) in 2016. However, not all
patients with CRC are referred via the SCC, and CRC is also found in patients undergoing a
routine colonoscopy.
Objective: To identify CRC cases in the Örebro Region and how they were identified.
Furthermore, to investigate the reasons for and possible effect of not being included in the
SCC-CRC for cases found via colonoscopy.
Methods: Reviewing medical records of patients with CRC referred to the Clinic of Surgery in
the Örebro Region in 2016-2018 (n=459).
The information recalled from the journals includes diagnostic pathway of CRC discovery, age,
gender, Body Mass Index (BMI), Hb-value, date of referral to colonoscopy, date of preformed
colonoscopy, referral route (SCC-CRC or non-CRC-SCC), reasons for referral (including SCC-CRC
criteria) and patient symptoms. Furthermore, we will gather data of tumor localization
(caecum; ascending colon; splenic flexure; transverse colon; hepatic flexure; descending
colon; sigmoid and rectum), TNM-stage of the tumor, [11] tumor differentiation (high grade or
low grade tumor), and source of referral (referral by general practitioner or referral by
hospital physician).
Age is determined at the time of referral. BMI is defined as the most recent BMI value at
time of referral within six months prior or six months after referral date. Hb-value will be
defined as the most recent Hb-value within a month prior of the time of referral. Diagnostic
interval is defined as the number of days days between the referral and the colonoscopy. When
the tumor localization is described as in between two locations of the colon (e.g. descendent
colon and sigmoid colon) the most proximal location is chosen for statistical analysis.
Patients with two or more synchronous cancers are registered as more than one incident per
case. When the tumor localization is described as being present in the rectosigmoid
transition, the sigmoid is used as the tumor localization in the analysis. When patients have
two or more symptoms and reasons for referral, data are registered as more than one incident
per case. TNM stage is converted to tumor stage I-IV. [1] When patients have one or more
synchronic cancer with different TNM stages, the highest cancer stage is chosen for analysis.
If the TNM stage is not fully known (e.g. information about lymph nodes and metastases are
missing) the stage is set as no lymph node engagement or metastases, If the original referral
cannot be found, date and reasons for referral are collected from journal entries.
2: The Swedish standardized course of care for colorectal cancer - cancer prevalence and
predictive values of entry criteria.
Introduction: To shorten waiting times for cancer treatment and to reduce national
inequalities in cancer care, the standardized course of care (SCC) was implemented in Sweden.
The SCC for colorectal cancer (CRC-SCC) was implemented in 2016. Since then, about 46.000
patients have been examined according to a CRC-SCC. However, few studies have been conducted
to evaluate the CRC-SCC.
Aim: To identify the prevalence of colorectal cancer (CRC) in patients referred to Örebro
University Hospital (USÖ) according to a CRC-SCC. We also aimed to investigate the positive
predicting values (PPVs) and odds ratios (ORs) of different SCC-criteria with respect to CRC.
Method: Medical record review including all patients examined by colonoscopy as part of a
CRC-SCC-referral to USÖ between September, 2016 and December 2018 (n=1271).The parameters of
interest include; patient characteristics such as sex and age, the SCC-criteria for
reasonable suspicion of cancer. If the patient has an altered bowel function it is registered
whether the patient has loose stool, constipation, a combination of the two, or not specified
in the referral. Rectal bleeding is defined as fresh rectal bleeding, excluding melaena.
Patients who fulfill multiple criteria are registered as more than one incidence case.
Laboratory values such as fecal occult blood, plasma-hemoglobin, and fecal-calprotectin
(F-calprotectin) are registered. The most resent value at the time of referral is used. If
there is no value within a month of the referral, no value was registered. A patient is
regarded to have a positive fecal occult blood test (FOBT) if at least one out of three tests
is positive. A f-calprotectin <50mg/kg is considered negative. Findings from the colonoscopy
such as CRC, polyps, inflammation of the colon, diverticulosis, hemorrhoids, angiodysplasia
or no finding are registered. All findings with colonoscopy are, if possible, histologically
verified.
3: Why do we perform gastroscopy in younger patients?
Background: Esophagogastroduodenoscopy (EGD) is the golden standard diagnostic method in
upper GI pathologies. The current guidelines indicate that patients with alarm symptoms
and/or dyspeptic patients over 50 years of age should be readily investigated with
gastroscopy. However, EGD is also frequently performed in the younger population, where it
often results in absence of pathological findings. In Örebro approximately 4000 EGD are
completed yearly, approximately 40% of the EGD's are performed in patients >50 years,
requiring extensive resources.
Aim: to identify factors in the EGD referrals of patients under 50 years of age without alarm
symptoms, in order to minimize the number of unnecessary EGD's in this age group.
Method and material: The study will be conducted as a retrospective database study. We will
process the EGD referrals and diagnostic findings of young patients (age 18-50 y) performed
during 2017-2019 at Örebro University Hospital. Statistical analysis will be performed to
identify which signs and symptoms are associated with a pathological finding during EGD and
which signs and symptoms are associated with a negative finding. The parameters of interest
include; patient characteristics such as sex and age will separately analyze the groups
18-29y, 30-39y, and 40-49 y. Other parameters include: BMI, ethnicity, use of NSAID/ASA, h.
pylori analysis, eventual treatment for h. pylori, smoking, alcohol consumption,presence of
GI disease before gastroscopy, previously done gastroscopy, source of referral (primary
health care or in-hospital patients), if present: fulfillment of Rome IV criteria for
functional dyspepsia, symptoms such as anemia, fecal occult blood, palpable mass in abdomen,
weight loss, loss of appetite, dysphagia, vomiting, jaundice, waiting time between referral
and gastroscopy, as well as the findings under gastroscopy; GERD/oesofagitis, peptic ulcus,
gastritis, dysplasia/cancer, IBD, celiac disease, hiatal hernia
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05074966 -
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
|
Phase 3 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT05056389 -
Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)
|
Phase 1 | |
Completed |
NCT04551014 -
Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm
|
N/A | |
Completed |
NCT04551001 -
Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy
|
N/A | |
Recruiting |
NCT04270500 -
The Impact of Physical Exercise on Sleep in Colorectal Cancer Patients During Prehabilitation Period
|
N/A | |
Recruiting |
NCT03667911 -
Virtual Reality Videos in Improving Bowel Preparation Quality of Colonoscopy
|
N/A | |
Not yet recruiting |
NCT04073680 -
A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05572684 -
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03567850 -
Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC
|
N/A | |
Recruiting |
NCT05870332 -
Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy
|
||
Completed |
NCT04534218 -
Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
|
Phase 2 | |
Enrolling by invitation |
NCT05590117 -
Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer
|
Early Phase 1 | |
Recruiting |
NCT03129139 -
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideā¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04195646 -
Computer Aided Detection of Polyps During Colonoscopy Procedures
|
N/A | |
Not yet recruiting |
NCT03618329 -
Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM.
|
N/A | |
Not yet recruiting |
NCT03261752 -
New Genes in the Carcinogenesis of Colorectal Cancer
|
||
Terminated |
NCT03621982 -
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
|
Phase 1 |